GSK, Pfizer RSV vaccine sales fall in US
Pfizer wins bid to invalidate 2 GSK patents relating to RSV vaccine
London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held by GlaxoSmithKline (GSK) that are related to a vaccine for
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.
Pfizer Wins London Court Battle, GSK's Respiratory Syncytial Virus Vaccine Patents Invalidated
On Monday, Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist investor Starboard Value has invested approximately $1 billion in Pfizer as the pharmaceutical giant grapples with a downturn in demand for COVID-19 vaccines and treatments.
Pfizer secures patent win at UK High Court in RSV vaccine race
The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving Pfizer, as both companies battle to become the first to launch an RSV vaccine on the UK market.
Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US as Millions Fewer People Line Up
A GSK spokesperson said 9 million Americans, or two-thirds of the market, have been vaccinated against RSV with Arexvy and that the company sees opportunities for strong growth in
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine. The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV,
U.K. court rules in Pfizer's favor in GSK RSV vaccine dispute: report
Pfizer (PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (GSK) patents for its RSV vaccine. Read more here.
Why Pfizer Will Find It Hard to Appease Its Activist Investor
The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.
pharmaphorum5d
A Pfizer consumer buyout won't detract from pharma business, says GSK chief
GlaxoSmithKline would consider buying Pfizer’s consumer health business – but only if the price is right, according to the company's chief executive. Emma Walmsley has also been busy shaking ...
TipRanks on MSN7d
Pfizer Sells $3.26B Stake in Haleon
Pfizer Inc. ($PFE) has sold its stake worth $3.26 billion in UK-based consumer healthcare company Haleon PLC ($GB:HLN). With ...
FiercePharma7d
Pfizer gins up £2.4B after unloading hundreds of millions of Haleon shares
Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...
Pfizer sells stake in Sensodyne and Panadol maker Haleon worth around £2.4bn
Pfizer sold 640 million shares in Haleon for 380p each, reducing its holding in the consumer healthcare firm by 7.6% ...
Business Times8d
Pfizer raises US$3.2 billion by selling part of Haleon stake
Pfizer has raised about US$3.2 billion from the sale of Haleon shares, as it further reduces its stake in the UK consumer ...